Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2014.03.151 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous infusion of angiotensin II for treatment of cardiopulmonary bypass-induced vasoplegic shock after implantation of left ventricular assist device: a case report.
Croat Med J
June 2023
Jasminka Peršec, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia,
We report on the first successful treatment of severe pharmacoresistant vasoplegic syndrome with angiotensin II acetate (ATII) in Croatia. ATII is a novel drug used to treat severe vasoplegic shock resistant to the administration of catecholamines or alternative vasopressors such as vasopressin or methylene blue. A 44-year-old patient with secondary toxic cardiomyopathy developed severe cardiopulmonary bypass-induced vasoplegic shock after scheduled implantation of a left-ventricular assist device.
View Article and Find Full Text PDFEfficacy of AutoPulse for Mechanical Chest Compression in Patients with Shock-Resistant Ventricular Fibrillation.
Int J Environ Res Public Health
February 2022
Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, 70-111 Szczecin, Poland.
Introduction: Sudden cardiac arrest is one of the most common causes of death. In cases of shock-resistant ventricular fibrillation, immediate transport of patients to the hospital is essential and made possible with use of devices for mechanical chest compression.
Objectives: The efficacy of AutoPulse in patients with shock-resistant ventricular fibrillation was studied.
Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest.
Heart
October 2022
Emergency Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
Objective: Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs. A Bayesian approach, combining the available evidence, may yield additional insights.
Methods: We conducted a reanalysis of the ALPS trial comparing treatment with amiodarone or lidocaine with placebo in patients with OHCA following shock-refractory ventricular fibrillation or ventricular tachycardia (VF/VT).
Coronary angiography findings in patients with shock-resistant ventricular fibrillation cardiac arrest.
Resuscitation
July 2021
Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Introduction: Shock-resistant ventricular fibrillation (VF) poses a therapeutic challenge during out-of-hospital cardiac arrest (OHCA). For these patients, new treatment strategies are under active investigation, yet underlying trigger(s) and substrate(s) have been poorly characterised, and evidence on coronary angiography (CAG) data is often limited to studies without a control group.
Methods: In our OHCA-registry, we studied CAG-findings in OHCA-patients with VF who underwent CAG after hospital arrival.
Importance of the distinction between recurrent and shock-resistant ventricular fibrillation: Call for a uniform definition of refractory VF.
Resuscitation
May 2019
Department of Cardiology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!